过氧化物酶体增殖物激活型受体δ的研究进展  

Research Advances in Peroxisome Proliferator-Activated Receptor delta

作　　者：王静[1] 夏军辉[1] 易光辉[1] 

机构地区：[1]南华大学心血管疾病研究所,湖南衡阳421001

出　　处：《心血管病学进展》2008年第B05期41-44,共4页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金(30570958);国家博士后科学基金资助金(20060400953);江苏省"135工程"开放课题资助项目

摘　　要：过氧化物酶体增殖物激活型受体(PPARs)是核受体超家族成员,在哺乳动物中存在3种亚型,即PPARα、PPARγ和PPARδ。PPARδ组织分布最广泛,参与脂肪组织和肌肉中脂肪酸氧化和能量解耦联,抑制巨噬细胞诱导的炎症。许多研究证明,激活组织中的PPARδ可以控制体重增加,增强身体耐力,提高胰岛素敏感性,改善动脉粥样硬化,从而为治疗代谢综合征提供了多方面治疗靶点。现重点阐述近年来PPARδ的研究进展。Peroxisome proliferator-activated receptors（ PPARs）are a family of three nuclear hormone receptors, PPARα, PPARδ, and PPARγ, which are members of the steriod receptor superfamily. PPARδ is expressed ubiquitously and is the most abundant of the three PPARs in most tissues. PPARδ enhances fatty acid catabolism and energy uncoupling in adipose tissue and muscle, and it suppresses macrophage-derived inflammation. Its combined activities in these and other tissues make it a muhifaceted therapeutic target for the metabolic syndrome with the potential to control weight gain, enhance physical endurance ,improve insulin sensitivity, and ameliorate atherosclerosis. In this review ,we focus mainly on the recently elucidated functions of PPARδ.

关 键 词：PPARΔ 代谢综合征 动脉粥样硬化 炎症 癌症 

分 类 号：R543.5[医药卫生—心血管疾病] Q78[医药卫生—内科学]